09.06.2021: The recent analysis of the global pipeline of antibacterials in clinical development from PEW and the WHO highlighted a stark picture of a broken antibiotics market unable to keep pace with the need for new drugs and that urgent action is needed to spur antibiotic innovation. This updated research has now been consolidated within the Dynamic Dashboard’s Pipeline Gallery, providing a tool to help policy makers and stakeholders monitor the antibacterial pipeline.
Read the joint communication from PEW, WHO and the Global AMR R&D Hub here
Link to the Dynamic Dashboard providing a consolidated overview of the clinical pipeline from PEW and the WHO: Global AMR R&D Hub Dashboard (globalamrhub.org)
29.04.2021: A special thanks to the expert consultation group who helped develop the plant and environment health specific categories of the Dynamic Dashboard.
Access our One Health Special Edition Newsletter here.
For any questions, suggestions, feedback or comments please email firstname.lastname@example.org
29.04.2021: Today is the official launch of the plant and environmental health data within our Dynamic Dashboard. With the addition of these data the Dynamic Dashboard covers all four One Health sectors – plant, environment, animal, human – and is now a truly global One Health AMR platform.
Visit the Dynamic Dashboard at https://dashboard.globalamrhub.org/
19.03.2021: What tools do National health systems have at their disposal to further reward the development and uptake of much needed new antibiotics and diagnostics? Undertaken by the team at the Austrian Institute of Public Health (GÖG), the Global AMR R&D Hub is happy to publicly-release this important study today. This comprehensive review of available policy tools within pricing, reimbursement and procurement in ten G20 countries, includes concrete examples and suggestions for learning, leverage and implementation. This is one of three studies that were used to derive our recently-published recommendations put forward to the G7 and G20 for their ongoing reflections. Download the full report here and the accompanying policy brief here.
04.03.2021: The Hub is proud to put forward to the G7 & G20, key emerging insights from its forthcoming studies that it was tasked to undertake by its board of members and G20 Leaders. The results of our initial studies reiterate the challenges that remain in the post-market space and propose concrete steps forward in accelerating antimicrobial development and access for building a more secure future ecosystem.
10.02.2021: The Hub is excited to announce a new collaboration with PAR Foundation, who will use the Dynamic Dashboard to help inform priorities for grant-making. We look forward to a successful partnership! Read the article here
28.01.2021: The Dynamic Dashboard now also shows data on projects financed by public and philanthropic funders that support human health-related AMR R&D addressing fungi. A short report with an initial analysis of the first set of more than 1000 such projects is available here.
28.01.2021: The Global AMR R&D Hub is pleased to announce the launch of the Funding Distributor Report in the Investment Gallery on the Dynamic Dashboard today. It shows funds going into and amount of funding going to activities supported by GARDP and CARB-X. You can access the report here https://dashboard.globalamrhub.org/reports/investments/funding-distributors
20.12.2020: The Global AMR R&D Hub would like to thank all participants that either attended or presented at our virtual conference held on 2 December 2020. The recordings of all three conference sessions are now available as is the conference report that highlights the recommendations arising from the discussions. Please click here
15.12.2020: In collaboration with the EU Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), the Global AMR R&D Hub publishes a policy brief “Incentivizing antibiotic access and innovation”. The brief presents the overall results from in-depth interviews with 13 countries – including 3 x outside of the EU. Findings include general support for antibiotic incentives, with the majority of interviewed countries preferring incentives that will secure access to both old and new antibiotics. Countries want more information on suitable multinational models and costs. Full manuscript is expected in 2021. Read the policy brief here.